



**MINISTRY OF BUSINESS,
INNOVATION & EMPLOYMENT**
HIKINA WHAKATUTUKI



From: 9(2)(a)
Sent: Tuesday, 30 March 2021 6:29 AM
To: 9(2)(a)
Cc: 9(2)(a)
Subject: 2021 CEPI Vaccine Manufacturing Landscape Assessment
Importance: High

CAUTION: This message was sent by an address external to CEPI. Please do not click on links or open attachments unless you recognize the source of this email and know the content is safe. Contact support@intility.no or it@cepi.net if uncertain.

Good Day,

I am reaching out to ask for your assistance in providing critical information to the combined effort of the Coalition for Epidemic Preparedness Innovation (CEPI) and the Bill & Melinda Gates Foundation (BMGF) to identify countries/regions in Africa, South East Asia, Latin America, and Middle East with either:

- Existing vaccine capacity/capability and requirements to develop these further to improve epidemic/pandemic preparedness and response options in future
AND/OR
- Countries or regions with aspirations to establish and/or improve vaccine capacity/capability that may currently be absent or limited

To that end, we are compiling a list of vaccine manufacturers with the capability, capacity, and willingness to support their efforts. We have identified you as a key member of the global vaccine manufacturing community and would like to ask if you would take a few minutes to complete the survey at the link below by the 31st of May 2021.

We understand that you are extremely busy and sincerely appreciate your help in this important initiative.

9(2)(b)(ii)

The data provided will help progress workshops to be run from 2H/2021 to develop a roadmap of vaccine manufacturing capacity and capability requirements to improve epidemic/pandemic preparedness and response in these 4 regions. Once the data have been received and processed, CEPI will share details of the workshops in the weeks after the survey deadline.

Please note this request for information does not represent a contract request, agreement, investment opportunity or intent. All provided data will be utilized for the internal purposes and processes by CEPI and, if to be shared without prior consent it will be anonymized and aggregated to avoid identification of any contributors. If data is to be shared revealing the contributing organization/s, then consent will be sought from them before doing so.

By selecting "Accept and Participate in Matchmaking" in the survey, the Respondent agrees to allow the use of data and information submitted herein by CEPI for the purposes of matching organizational capabilities with potential manufacturing projects or needs including introducing to those with potential needs. The Respondent acknowledges that this is not a guarantee of work or projects and cannot be construed as a contract request, agreement, investment opportunity or intent.

****Note that the answers you provide may influence the questions that you receive later in the survey. Attached is a PDF preview of the questions in the online survey so that you may prepare the necessary information for your submission ahead of time. If you have technical issues accessing the survey, please reach out to 9(2)(a) with any questions.****

Kind Regards,

9(2)(a)

Latham
BIOPHARM GROUP
www.LathamBioPharm.com

www.govt.nz - your guide to finding and using New Zealand government services

Any opinions expressed in this message are not necessarily those of the Ministry of Business, Innovation and Employment. This message and any files transmitted with it are confidential and solely for the use of the intended recipient. If you are not the intended recipient or the person responsible for delivery to the intended recipient, be advised that you have received this message in error and that any use is strictly prohibited. Please contact the sender and delete the message and any attachment from your computer.

www.govt.nz - your guide to finding and using New Zealand government services

Any opinions expressed in this message are not necessarily those of the Ministry of Business, Innovation and Employment. This message and any files transmitted with it are confidential and solely for the use of the intended recipient. If you are not the intended recipient or the person responsible for delivery to the intended recipient, be advised that you have received this message in error and that any use is strictly prohibited. Please contact the sender and delete the message and any attachment from your computer.

RELEASED UNDER THE
OFFICIAL INFORMATION ACT

From: Michael Contaldo
Sent: Wednesday, 26 May 2021 1:13 PM
To: Nidish Nair
Subject: RE: [WARNING MESSAGE ENCRYPTED]FW: 2021 CEPI Vaccine Manufacturing Landscape Assessment [UNCLASSIFIED]

Great. Thanks for letting me know.

Michael

From: Nidish Nair <nidish.nair@biocellcorp.co.nz>
Sent: Wednesday, 26 May 2021 11:55 AM
To: Michael Contaldo <Michael.Contaldo@mbie.govt.nz>
Subject: RE: [WARNING MESSAGE ENCRYPTED]FW: 2021 CEPI Vaccine Manufacturing Landscape Assessment [UNCLASSIFIED]

Hello Michael,

I just wanted to let you know that we have completed/submitted this survey.

Have a great week.

Cheers,

Nidish

From: Michael Contaldo <Michael.Contaldo@mbie.govt.nz>
Sent: Friday, 21 May 2021 2:53 PM
To: Nidish Nair <nidish.nair@biocellcorp.co.nz>
Subject: RE: [WARNING MESSAGE ENCRYPTED]FW: 2021 CEPI Vaccine Manufacturing Landscape Assessment [UNCLASSIFIED]

Great – thanks Nidish

From: Nidish Nair <nidish.nair@biocellcorp.co.nz>
Sent: Friday, 21 May 2021 1:39 PM
To: Michael Contaldo <Michael.Contaldo@mbie.govt.nz>
Subject: RE: [WARNING MESSAGE ENCRYPTED]FW: 2021 CEPI Vaccine Manufacturing Landscape Assessment [UNCLASSIFIED]

Hello Michael,

Thank you for your email.

Agree that it would be useful to remain engaged with CEPI and where possible assist in their global efforts.

I can confirm that we will complete the survey prior to the deadline of 31 May.

Have pleasant weekend.

Cheers,

Nidish

From: Michael Contaldo <Michael.Contaldo@mbie.govt.nz>

Sent: Friday, 21 May 2021 10:39 AM

To: Nidish Nair <nidish.nair@biocellcorp.co.nz>

Subject: [WARNING MESSAGE ENCRYPTED]FW: 2021 CEPI Vaccine Manufacturing Landscape Assessment [UNCLASSIFIED]

Importance: High

Dear Nidish – hope all is well.

We've been speaking recently to the Centre for Epidemic Preparedness Innovations (CEPI). They are doing some work to better understand global capabilities in vaccine manufacture to support their forward strategy.

We've been invited to submit information on firms in New Zealand with this potential capacity and think it could be useful to remain engaged with CEPI's work as far as we can.

We wondered therefore whether Biocell would be interested in completing the survey which is being coordinated by Lathan Biopharm on their behalf? The survey is relatively straightforward. It can be accessed through the link below. The deadline is **31 May** so apologies for only reaching out now. We had previously thought the survey was limited to south east Asia but following a recent conversation with CEPI it seems they are also interested in understanding capacity in the Pacific region.

If you decide not to take part that's also fine. But if you could let me know either way then that would be great.

Kind regards/ Michael

Michael Contaldo (he/him)

Principal Policy Advisor, Innovation Policy

Mobile – Waea Tōtika: 9(2)(a)

Email - Īmera: Michael.contaldo@mbie.govt.nz

Postal – Poutāpeta: 15 Stout Street, Wellington 6140 | New Zealand

Website – Pae-ipurangi: www.mbie.govt.nz

From: Nidish Nair <nidish.nair@biocellcorp.co.nz>
Sent: Friday, 6 August 2021 10:21 AM
To: Simon Rae
Cc: Pooja Dave
Subject: Re: Phone call request [UNCLASSIFIED]
Attachments: Press Release.Filling machine.August21.pdf

Thank you for your email, Simon.

I assumed that you would be snowed under and was typing this email to you when your email popped up.

We are intending to do a press release on Monday/Tuesday next week (please see attached). Would you please let me know if you have any concerns with the content?

Pooja, would you please suggest some time slots for a phone call that would work for Simon next week?

Cheers,

Nidish

From: Simon Rae <Simon.Rae@mbie.govt.nz>
Sent: Friday, 6 August 2021 9:58 AM
To: Nidish Nair <nidish.nair@biocellcorp.co.nz>
Cc: Pooja Dave <Pooja.Dave@mbie.govt.nz>
Subject: RE: Phone call request [UNCLASSIFIED]

Hi Nidish,

It would be good to have a chat. The last few days have been quite busy, and today's a write off. It might be easiest to set up a time? My PA Pooja can assist.

Simon

From: Nidish Nair <nidish.nair@biocellcorp.co.nz>
Sent: Tuesday, 3 August 2021 12:50 PM
To: Simon Rae <Simon.Rae@mbie.govt.nz>
Subject: Phone call request

Hello Simon,

I trust you and the team are keeping well.

I was wondering if you would please be available for a quick call either today or in the next couple of days.

It would be great to discuss a couple of matters with you including an upcoming press release.

Cheers,

Nidish

Nidish Nair

CEO

nidish.nair@biocellcorp.co.nz | www.biocellcorp.co.nz



19 Laureston Avenue, Papatoetoe, Auckland, 2025, NZ

www.govt.nz - your guide to finding and using New Zealand government services

Any opinions expressed in this message are not necessarily those of the Ministry of Business, Innovation and Employment. This message and any files transmitted with it are confidential and solely for the use of the intended recipient. If you are not the intended recipient or the person responsible for delivery to the intended recipient, be advised that you have received this message in error and that any use is strictly prohibited. Please contact the sender and delete the message and any attachment from your computer.

RELEASED UNDER THE
OFFICIAL INFORMATION ACT

Assembly of the automated vaccine filling machine for New Zealand's Biocell Corporation begins in Germany

Biocell Corporation is excited that final assembly of the automated vaccine vial filling machine has begun in Germany. All of the software programming/integration and machining tasks are complete. Following assembly, the final stage of "factory acceptance testing" will be conducted to ensure it meets the required specifications and this is scheduled to begin in September. Nidish Nair, Biocell's CEO, is delighted that the vaccine vial filling machine is on target for completion and shipping by the end of September. Increased demand on vaccine related equipment, along with delays and blockages in international supply chains and logistics, has added pressure globally as businesses continue to build capability and capacity for domestic vaccine production.

Funding from the NZ government's Covid 19 vaccine strategy has enabled Biocell Corporation to secure this high-quality automated filling system. At capacity, the filling machine will have the ability to fill up to 100 million vaccine doses a year. The new automated filling machine has the latest technologies to ensure both accuracy and sterility of the vaccine doses. According to Nair, "the addition of this machine will be a significant boost to the NZ biotechnology and pharmaceutical sector. The capacity increase will enable the potential supply of life saving vaccines to not just NZ and the pacific islands but also to the greater international community."

The German manufacturer supplying the filling system to Biocell also manufactures filling machines for other key global pharmaceuticals including the companies that are filling Pfizer/BioNTech and Moderna vaccines. The addition of the filling machine to Biocell's existing GMP compliant facility will open up co-operation and collaboration opportunities for NZ to work with pharmaceutical companies to fill vaccines in NZ that have already been registered. Biocell Corporation has been manufacturing viral vaccines for over 30 years in their Auckland manufacturing site and have a highly capable team of scientific and technical employees.